Publicaciones en las que colabora con IDOIA MARTIN GUERRERO (23)

2024

  1. CircRNAome of Childhood Acute Lymphoblastic Leukemia: Deciphering Subtype-Specific Expression Profiles and Involvement in TCF3::PBX1 ALL

    International Journal of Molecular Sciences, Vol. 25, Núm. 3

2023

  1. Decoding the molecular heterogeneity of pediatric monomorphic post–solid organ transplant lymphoproliferative disorders

    Blood, Vol. 142, Núm. 5, pp. 434-445

  2. Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification

    Acta Neuropathologica, Vol. 145, Núm. 5, pp. 651-666

2022

  1. Diverse mutations and structural variations contribute to Notch signaling deregulation in paediatric T-cell lymphoblastic lymphoma

    Pediatric Blood and Cancer, Vol. 69, Núm. 11

  2. Identification and Functional Analysis of a Novel CTNNB1 Mutation in Pediatric Medulloblastoma

    Cancers, Vol. 14, Núm. 2

2020

  1. Distinct molecular profile of IRF4-rearranged large B-cell lymphoma

    Blood, Vol. 135, Núm. 4, pp. 274-286

  2. Role of rs10406069 in miR-5196 in hyperdiploid childhood acute lymphoblastic leukemia

    Epigenomics, Vol. 12, Núm. 22, pp. 1949-1955

  3. Variability in Cerebrospinal Fluid MicroRNAs Through Life

    Molecular Neurobiology, Vol. 57, Núm. 10, pp. 4134-4142

2019

  1. Variants in vincristine pharmacodynamic genes involved in neurotoxicity at induction phase in the therapy of pediatric acute lymphoblastic leukemia

    Pharmacogenomics Journal, Vol. 19, Núm. 6, pp. 564-569

2018

  1. Involvement of SNPs in miR-3117 and miR-3689d2 in childhood acute lymphoblastic leukemia risk

    Oncotarget, Vol. 9, Núm. 33, pp. 22907-22914

  2. Involvement of miRNA polymorphism in mucositis development in childhood acute lymphoblastic leukemia treatment

    Pharmacogenomics, Vol. 19, Núm. 18, pp. 1403-1412

  3. Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia

    Pharmacogenomics Journal, Vol. 18, Núm. 6, pp. 704-712

  4. Pharmacoepigenetics in childhood acute lymphoblastic leukemia: Involvement of miRNA polymorphisms in hepatotoxicity

    Epigenomics, Vol. 10, Núm. 4, pp. 409-417

  5. Role of miRNAs in treatment response and toxicity of childhood acute lymphoblastic leukemia

    Pharmacogenomics, Vol. 19, Núm. 4, pp. 361-373

2017

  1. Confirmation of involvement of new variants at CDKN2A/B in pediatric acute lymphoblastic leukemia susceptibility in the Spanish population

    PLoS ONE, Vol. 12, Núm. 5

2016

  1. A systematic review and meta-analysis of MDM2 polymorphisms in osteosarcoma susceptibility

    Pediatric Research, Vol. 80, Núm. 4, pp. 472-479

  2. MIR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia

    Pharmacogenetics and Genomics, Vol. 26, Núm. 11, pp. 517-525

  3. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia

    Pharmacogenomics, Vol. 17, Núm. 7, pp. 731-741

2014

  1. Methylation of the nonhomologous end joining repair pathway genes does not explain the increase of translocations with aging

    Age, Vol. 36, Núm. 6

  2. Noncoding RNA-related polymorphisms in pediatric acute lymphoblastic leukemia susceptibility

    Pediatric Research, Vol. 75, Núm. 6, pp. 767-773